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NARRATIVE REVIEW

Pharmacotherapy in Coronavirus Disease 2019
and Risk of Secondary Infections: A Single-Center
Case Series and Narrative Review
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OBJECTIVES: Since the onset of the coronavirus disease 2019 pandemic,
immune modulators have been considered front-line candidates for the management of patients presenting with clinical symptoms secondary to severe acute
respiratory syndrome coronavirus 2 infection. Although heavy emphasis has been
placed on early clinical efficacy, we sought to evaluate the impact of pharmacologic approach to coronavirus disease 2019 within the ICU on secondary infections and clinical outcomes.
DATA SOURCES: PubMed (inception to March 2021) database search and
manual selection of bibliographies from selected articles.
STUDY SELECTION AND DATA EXTRACTION: Articles relevant to coronavirus disease 2019, management of severe acute respiratory syndrome coronavirus 2–associated respiratory failure, and prevalence of secondary infections with
pharmacotherapies were selected. The MeSH terms “COVID-19,” “secondary infection,” “SARS-CoV-2,” “tocilizumab,” and “corticosteroids” were used for article
identification. Articles were narratively synthesized for this review.
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DATA SYNTHESIS: Current data surrounding the use of tocilizumab and/or corticosteroids for coronavirus disease 2019 management are limited given the short
follow-up period and conflicting results between studies. Further complicating the
understanding of immune modulator role is the lack of definitive understanding of
clinical impact of the immune response in coronavirus disease 2019.
CONCLUSIONS: Based on the current available literature, we suggest prolonged trials and follow-up intervals for those patients managed with immune
modulating agents for the management of coronavirus disease 2019.
KEY WORDS: acute respiratory failure; coronavirus
immunomodulation; infectious disease; secondary infections
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2019;

he report of a novel betacoronavirus, severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), was first reported in Wuhan, China, in
December of 2019 (1). SARS-CoV-2 and its resulting disease, coronavirus disease 2019 (COVID-19), quickly spread worldwide, classified as a pandemic by the World Health Organization (WHO) in March 2020. Given the
rapid spread and global impact, the medical community was forced to quickly
grow and evolve to treat this novel disease. Several treatment considerations
showed early signals of benefit in small clinical cohorts but have shown conflicting results in larger trials (2, 3). Many of these treatments are immunomodulatory and activate or suppress certain immunologic functions with the
intent of assisting the endogenous immune response to the virus. Through
increased knowledge regarding host response to the disease and further evaluation of clinical data, potential immunologic implications of both the disease
and immunomodulatory therapies have been elucidated.
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PATHOPHYSIOLOGY AND
IMMUNOSUPPRESSION
SARS-CoV-2 resembles the pathophysiology of severe acute respiratory syndrome and Middle East respiratory syndrome, the two prior coronaviruses known
to cause pneumonia, respiratory failure, and death
(4, 5). The way by which SARS-CoV-2 invades host cells,
resulting in profound activation of the innate immune
system, subsequent cytokine release, and multiple organ
failure, is shown in Figure 1 (5, 6). Elevation in blood cytokine levels is a common laboratory finding in SARSCoV-2 patients, notably interleukin (IL)–6, IL-7, and
IL-10 (7).
An early and strong type-1 interferon (IFN) response is needed to suppress viral replication (8, 9).
Type-1 IFNs constitute the largest family of IFNs in
humans and include IFN-α, IFN-β, IFN-e, IFN-k, and
IFN-w (10, 11). Intracellular RNA degradation, viral
clearance, tissue repair, and extended adaptive immune

response are key immunologic pathways facilitated by
type-1 IFNs (12). Previous studies conducted with
other coronavirus strains indicate these viruses exhibit a potent inhibition of early type-1 IFN response
leading to hyperinflammation, and it is theorized that
SARS-CoV-2 also exhibits this inhibition (13–16).
As infection persists, the host immunologic state is
characterized by immune cell apoptosis, lymphocyte dysfunction, and lymphopenia (Fig. 2). T cell response to
SARS-CoV-2 is weakened and predisposes the host to persistent immunologic impairment and progression to latestage infection (17). It is clear that T-cell dysfunction is a
significant contributor to immunologic status at all stages
of disease, leading to persistent cytokine release, inflammatory activation, and subsequent immunosuppression.
Increased susceptibility to secondary bacterial, fungal,
and viral infections is a concern and has been described
in respiratory viral infections (18). Various mechanisms
have been implicated including endothelial cell dysfunction, vascular leakage, decreased mucus clearance,

Figure 1. Pathophysiology of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. SARS-CoV-2 spread via
respiratory droplets and enters the human cell via S-protein envelope binding with human angiotensin receptor-2 (hACE2). Once viral
fusion is complete, the virus is endocytosed, and viral RNA uses host cellular components to replicate and spread. As SARS-CoV-2
viral load peaks, the innate immune system becomes activated and a cytokine storm ensues, with release of tumor necrosis factor
alpha (TNF-a), interferon gamma (IFN-y), granulocyte colony-stimulating factor (G-CSF), and various other interleukins (IL). Rapid
viral replication leads to epithelial and endothelial apoptosis, vascular leakage, profound inflammation resulting in multisystem organ
dysfunction. As infection persists, the host enters a state of immune exhaustion characterized by T-cell dysfunction, lymphopenia, and
suppressed type-1 interferon response.
2     www.ccejournal.org
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Figure 2. Immunologic consequences of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)–associated
immunosuppression. As infection persists, the host enters a state of immune exhaustion. A delayed or suppressed type-1 interferon
(IFN) response leads to T-cell dysfunction and ultimately exhaustion. Furthermore, viral-induced immune cell apoptosis results in
lymphopenia with decreases in all lymphocyte subtypes. Continued activation of the inflammatory cascade leads to increasing levels of
inflammatory cytokines and hyperinflammation. Hyperinflammation paired with immune exhaustion places patients at an increased risk of
secondary infectious complications. CCL = C–C motif chemokine ligand, CXCL = C-X-C motif chemokine ligand, IL = interleukin,
NK = natural killer, TNF-a = tumor necrosis factor alpha.

promotion of biofilm formation, and microbiome alterations (18–21). Primary viral infections can also trigger reactivation of latent viruses such as herpes simplex virus
(HSV) or varicella zoster virus. Prolonged fever and cytokine release which damage neurons and tissues where
these viruses remain latent has led to reactivation in various inflammatory states (22). Both are common clinical
Critical Care Explorations

manifestations of SARS-CoV-2 infection and may present further risk. These mechanisms, in addition to the
previously described immunologic dysfunction, present
a significant risk for secondary infections in patients with
SARS-CoV-2.
Reports of secondary bacterial infections in SARSCoV-2 patients vary from 4% to 25%, reaching up to
www.ccejournal.org
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50% in nonsurvivors (23, 24). Patients admitted to
the ICU often require mechanical ventilation or extracorporeal membrane oxygenation (ECMO), which
present additional risk factors (25–28). Common
bacterial pathogens include Staphylococcus aureus,
Pseudomonas aeruginosa, and Enterococcus species.
Data on fungal secondary infections are less abundant
compared with bacterial infections, but Candida species appear to be the most common fungal pathogen
encountered (29). There are also increasing reports
of SARS-CoV-2–associated pulmonary aspergillosis
similar to that seen with previous influenza outbreaks
(30–33). However, larger studies are conflicting on the
true prevalence and risk of fungal secondary infections in this population (34–36). Regarding viral secondary infections, previously reported rates of HSV
reactivation range from 21% to 57% in ICU patients
(37, 38). Only one study has specifically evaluated
the frequency of HSV reactivation in SARS-CoV-2
patients and found a reactivation rate of 23.6% (39).
Although the immunologic effects of SARS-CoV-2 impose risks for secondary infections, utilization of treatment modalities with immunosuppressive properties,
such as tocilizumab and corticosteroids, may confer
additional risk.
Tocilizumab is a recombinant, humanized monoclonal antibody that competitively antagonizes both
soluble and membrane-bound IL-6 receptors, preventing IL-6 signal transduction and leading to significant
immunosuppression (40). Current literature suggests
tocilizumab may reduce the need or duration of mechanical ventilation, progression to severe disease, or
death, but results are inconsistent (2, 3, 41–44). Reports
of infectious complications in SARS-CoV-2 patients
treated with tocilizumab are also inconsistent and limited in follow-up compared with previous tocilizumab
trials (45–47).
Additionally, corticosteroids possess potent immunosuppressant properties, and infectious complications have been well-documented with use of oral
corticosteroids for rheumatologic conditions (48–50).
The effect is dose-dependent, with every increase of
5 mg daily of prednisone and 1,000 mg cumulative
dose in the last year increasing the risk of all-cause infection by 13% and 50%, respectively. Even short-term
use of prednisone has demonstrated a higher risk of
sepsis within 30 days of initiation (50). Similar findings have been documented in critically ill patients
4     www.ccejournal.org

receiving corticosteroids, with significant increases in
pneumonia (odds ratio [OR], 2.64; CI, 1.21–5.75) and
bacteremia (OR, 3.25; CI, 1.26–8.37) (51).
Considering the associations with infection previously reported with tocilizumab and corticosteroid
administration, these therapies may pose similar risks
following their use in patients with SARS-CoV-2. The
aim of this study was to characterize the incidence of
secondary infections in patients with SARS-CoV-2
infection admitted to a single-center ICU. We also
provide an in-depth review of the available literature
regarding secondary infections following tocilizumab
and corticosteroid therapy in SARS-CoV-2 patients.

METHODS
This was a retrospective case series conducted at
University of Kentucky Healthcare, which is a tertiary
care referral academic medical center. This study was
approved by the University of Kentucky HealthCare
Institutional Review Board (approval number 47751).
Due to the retrospective nature, informed consent was
waived. The electronic health record for patients admitted to the medical ICU at our institution with a positive
SARS-CoV-2 test from March 2020 to November 2020
was reviewed. Data including baseline demographics,
clinical variables, and outcomes including secondary
infections were collected in a standardized data collection form. Baseline immunosuppression was defined
as presence of functional immunosuppressive disorders, autoimmune disorders, or home medications
with known immunosuppressive properties prior to
admission.
Secondary infections were defined as a new infection with onset greater than 48 hours from initial ICU
admission, including ICUs at outside hospitals. These
infections were identified via microbiologic results
positive for new bacterial, viral, and fungal pathogens
requiring anti-infective implementation. In addition
to the aforementioned criteria, fungal secondary infections were also identified based on an elevated betaD-glucan (BDG) that was treated with an antifungal
agent. Viral secondary infections were identified
based on a positive polymerized chain reaction test.
Treatment variables were found via the medication administration record. Cases were adjudicated by review
of the primary team notes and treatment decisions.
Candida species that grew in the urinary or respiratory
July 2021 • Volume 3 • Number 7
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tract and coagulase-negative Staphylococcus blood cultures which were deemed noninfectious by the treating
team were not included.
The authors also conducted a MEDLINE/PubMed
database search from inception to April 2021, and
bibliographies were manually selected from selected
articles. The MeSH terms “COVID-19,” “secondary
infection,” SARS-CoV-2,” “tocilizumab,” and “corticosteroids” were used for article identification. Articles
relevant to COVID-19, management of SARS-CoV2–associated respiratory failure, and incidence of
secondary infections with pharmacotherapies were
selected. Articles were narratively synthesized for this
review.

RESULTS
Over a period of 6 months, we analyzed 237 patients
who presented to the ICU with SARS-CoV-2 complicated by acute respiratory failure (Table 1). On average, patients in our case series were elderly, obese,
and more than 60% were diagnosed with diabetes
prior to admission (Table 1). One-hundred eleven
patients (46.8%) were transferred from an outside hospital where they had been admitted for an average of 7
days before transfer. Baseline immunosuppression was
present in 87 patients (36.7%). The need for mechanical ventilation was high at 75%, whereas ECMO was
used in 12.7% of patients. Tocilizumab use was infrequent; however, corticosteroids were administered to
a majority of patients. In those patients who received
tocilizumab, only three (10%) did not receive concomitant corticosteroids. There were 18 patients who did
not receive tocilizumab or dexamethasone during ICU
admission. Seventy-six patients (32.1%) died during
their admission, and the majority died while in the
ICU. Overall, our patients experienced ICU and hospital lengths of stay of 16 ± 16 days and 24 ± 18 days,
respectively.
Of the 237 patients included in this case series,
110 (46.4%) developed a secondary infection, and a
total of 173 secondary infections were identified. In
patients with a secondary infection, 55 (50%) had one
secondary infection, 31 (23.2%) had two secondary
infections, 14 (12.7%) had three secondary infections,
and 10 (9.1%) had four or more secondary infections (Table 1). Respiratory (49%) and bloodstream
(27.6%) were the most common sources of infection
Critical Care Explorations

(Supplementary Table 1, http://links.lww.com/CCX/
A717). Common respiratory pathogens included both
Gram-positive and Gram-negative organisms, whereas
bloodstream pathogens were mainly Gram-positive
organisms. Regarding fungal secondary infections,
most were identified as Candida species or an elevated
BDG treated with an antifungal agent. Only one case of
aspergillus was identified in a respiratory culture. The
only virial secondary infection identified was HSV reactivation which occurred in 17 patients (7.2%).
Patients developing secondary infections had higher
rates of baseline immunosuppression, diabetes, need
for ventilator and ECMO support, and vasopressor use.
These patients also experienced greater rates of reintubation, longer ICU and hospital lengths of stay, and
higher mortality rates. Of the 30 patients who received
tocilizumab, 11 (36.7%) experienced a secondary infection. Notably, of the three patients who received
tocilizumab monotherapy, no incidences of secondary
infection were seen. Additionally, 213 patients (89.9%)
received corticosteroids, and 106 (49.8%) developed a
secondary infection. All patients who had HSV reactivation received corticosteroids during their ICU admission. Of the 27 patients who received tocilizumab
in combination with corticosteroids, 11 (40.7%) developed secondary infections. In those patients not
receiving corticosteroids or tocilizumab, fours (22%)
developed a secondary infection. Supplemental Table 2
(http://links.lww.com/CCX/A718) further summarizes the incidence of secondary infections by therapeutic intervention.

DISCUSSION AND REVIEW OF
LITERATURE
Case Series
Our findings suggest a high prevalence of secondary
infections in patients with SARS-CoV-2, especially
bacterial pneumonia and bloodstream infections.
In our study, 46.4% of patients developed secondary
infections compared with 4–25% previously reported
(23). The higher prevalence reported in our study may
reflect the vast differences in patient populations. In
our case series, more than 60% of patients were diagnosed with diabetes prior to admission, whereas previous reports had a much lower incidence of diabetes
ranging from 16.3% to 22.6% (30). Previous studies
have shown those with diabetes are three times more
www.ccejournal.org
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TABLE 1.

Demographics and Outcomes of Patient Population
No Secondary
Infection (N = 127)

Secondary
Infection (N = 110)

Overall
(N = 237)

Age, yr, mean, sd

62.1, 14.2

58.9, 13.3

61, 14

Female gender, n (%)

74 (58.3)

67 (60.9)

96 (40.5)

Body mass index, kg/m2, mean, sd

33.9, 7.9

35.9, 11.2

34.8, 9.6

Immunosuppression at baseline, n (%)a

37 (29.1)

50 (45.5)

87 (36.7)

Diabetes, n (%)

72 (56.7)

73 (66.4)

145 (61.2)

Source, OSH, n (%)

52 (40.9)

59 (53.6)

111 (46.8)

OSH duration prior to transfer, days, mean, sd

5.4, 4.4

8.9, 6.8

7.3, 6.0

Source, floor, n (%)

1 (0.8)

0 (0)

20 (8.4)

58 (45.7)

38 (34.5)

96 (40.5)

Source, long-term acute care facility/nursing home, n (%)

5 (3.9)

5 (4.5)

10 (4.2)

Days since onset, mean, sd

8.6, 5.7

9.7, 6.7

9.1, 6.2

Mechanical ventilation, n (%)

76 (59.8)

103 (93.6)

179 (75.5)

Extracorporeal membrane oxygenation, n (%)

9 (7.0)

21 (19.1)

30 (12.7)

Reintubation, n (%)

5 (3.9)

18 (16.4)

23 (9.7)

ICU mortality, n (%)

26 (20.5)

47 (42.7)

73 (30.8)

Hospital mortality, n (%)

28 (22.1)

48 (43.6)

76 (32.1)

ICU readmission, n (%)

3 (2.4)

5 (4.5)

8 (3.4)

Hospital duration, d, mean, sd

19.3, 16.1

28.7, 18.2

23.61, 17.73

ICU duration, d, mean, sd

11.7, 13.3

21.7, 17.0

16.31, 15.94

516.9, 516.6

240.5, 133.8

228.1, 385.4

4.6, 5.6

4.7, 5.1

4.651, 5.4

79.7, 77.6

49.9, 113.3

65, 95

177.3, 68.4

134.1, 61.8

157, 68.7

6.6, 4.3

6.8, 5.0

6.69, 4.64

One

—

55 (50)

55 (23.2)

Two

—

31 (25.2)

31(13.1)

Three

—

14 (12.7)

14 (5.9)

Four or more

—

10 (9.1)

10 (4.2)

Variables

Source, emergency department, n (%)

Maximum C-reactive protein, mg/L, mean, sd
Maximum d-dimer, µg/mL, mean, sd
Maximum interleukin-6, pg/mL, mean, sd
Minimum platelets, k/mc, mean, sd
Minimum WBC, k/mc, mean, sd
Number of infections, n (%)

Renal replacement therapy, n (%)

20 (15.8)

42 (38.2)

62 (26.2)

Vasopressor, n (%)

56 (44.1)

95 (86.4)

151 (63.7)

107 (84.3)

106 (96.4)

213 (89.9)

Remdesivir, n (%)

77 (60.6)

71 (64.5)

148 (62.5)

Tocilizumab, n (%)

19 (15.0)

11 (10)

30 (12.7)

Hydroxychloroquine, n (%)

10 (7.9)

Steroids, n (%)

7 (6.4)

17 (7.2)

— = not applicable, OSH = outside hospital.
a
Defined as receiving immunosuppressive therapies or presence of immunosuppressive disease state prior to admission.
6     www.ccejournal.org
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likely to develop bacterial infections due to defective
phagocytes (52, 53). Additionally, immunomodulatory treatment with steroids was higher in our case series (30). Our case series focused only on a medical
ICU population, whereas previous reports included
patients outside of the ICU (30).
In a recent analysis, authors report the differences
in the immune response between COVID-19 and
bacterial sepsis (54). Immune cell profiles differed
between mild and severe COVID-19 patients with severity being associated with unique immune profiles
compared with sepsis, with persistent and profound
depletion in lymphocyte subsets as well as reduction in human leukocyte antigen-DR on circulating
monocytes expression. Findings supported the onset
of strong and durable immune suppression together
with an elevated incidence of ICU-acquired infections
of 60% in those with COVID-19. Thus, using immunomodulating therapies in the treatment of SARS-CoV-2
might impact ICU-acquired infections, which supports
our findings of increased risk of secondary infections
in patients receiving corticosteroids or tocilizumab.
Rates of HSV reactivation in our population were 7.2%
which is much lower than 23.6% reported by the only
published study specifically looking at this outcome
(39). As previously mentioned, tocilizumab and corticosteroids exhibit immunosuppressive effects that can
contribute to the development of secondary infections.
We now present a review of the available literature on
secondary infections associated with tocilizumab and
corticosteroid use in SARS-CoV-2 patients. To our
knowledge, this is the only expansive review of secondary infections with these two immunomodulatory
therapies in SARS-CoV-2 patients.
Tocilizumab
A summary of studies reporting secondary infections
in SARS-CoV-2 patients treated with tocilizumab is
presented in Supplementary Table 3 (http://links.lww.
com/CCX/A719). In small studies, tocilizumab has
been associated with a 16–54% incidence of secondary
infections (24, 55–62). In a large study of 3,580 patients
with SARS-CoV-2, 497 patients received tocilizumab
and were four times as likely to develop secondary infections compared with standard of care (63). However,
two prospective, randomized, double-blind, placebocontrolled trials investigating tocilizumab compared
Critical Care Explorations

with standard of care did not report a significant difference in secondary infections between groups (64, 65).
The most recently published randomized trials also
found no difference in bacterial secondary infections
in patients treated with tocilizumab compared with
standard of care; however, nonsevere secondary infections were not included. 43, 44, 66). It should be noted,
the definition of secondary infection was not reported
for a majority of these previous trials. For studies providing a definition, secondary infections were most
commonly identified based on positive microbiologic
cultures. Follow-up duration also varied significantly
among studies ranging from 10 to 47 days, with some
studies not reporting a follow-up duration.
Tocilizumab use was less frequent in our study
compared with prior studies, and this could be largely
due to our study period as this was conducted prior to
many of the large, randomized, controlled trials showing efficacy of tocilizumab. However, our secondary
infection rate of 36.7% following tocilizumab use is in
line with rates previously reported.
Although much less reported in current literature,
viral reactivation has also been described following administration of tocilizumab. HSV reactivation
was noted in one patient from a small cohort study,
whereas another study reported one patient with hepatitis B virus reactivation and four patients with HSV
reactivation (55, 58). Similar results were seen in our
population with only two patients experiencing HSV
reactivation who received tocilizumab, further supporting a potential low risk for viral reactivation following tocilizumab therapy in SARS-CoV-2 patients.
In patients with rheumatoid arthritis, a Japanese postmarketing registry estimated the rate of HSV to be
2.2 episodes per 100 patient-years, and in the United
States, this was conducted using U.S. Medicare data
with the incidence of HSV of 2.15 episodes per 100
patient-years with no differences compared with other
biologics (67, 68).
It is unclear how long the immunosuppressive effects
persist after single or subsequent doses of tocilizumab
and may lead to infectious complications later during
the hospital course. A 2011 meta-analysis reported a
rate of serious infection of 4.9 per 100 patient-years
among patients receiving tocilizumab doses of 8 mg/kg
and lower for those receiving placebo or 4 mg/kg (3.5
per 100 patient-years) in a rheumatoid arthritis longterm safety analysis (69). The type of infection ranged
www.ccejournal.org
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from pneumonia, urinary tract infections, and cellulitis. Those who were older than 65 years old reached
an incident rate of 8.5 episodes per 100 patient-years.
Authors found the rate of serious infections remained
relatively stable with continued tocilizumab treatment;
thus, the potential to impact rates of serious infection is
likely due to tocilizumab’s rapid onset of action leading
to reductions of inflammatory markers with prompt
suppression of inflammation. Furthermore, in adult
patients with rheumatoid arthritis, the half-life ranges
from 11 to 13 days (70). In clinical trials of rheumatoid arthritis, tocilizumab has been administered once
every 4 weeks. Considering the risk of secondary infections and the apparent half-life of tocilizumab, it is logical to consider the need for long-term infection risk
follow-up in patients receiving tocilizumab in the setting of COVID-19. In our case series, the overall hospital duration was 23.6 days. Considering the half-life
of tocilizumab, our case series likely did not capture
the true incidence of secondary infections attributed
to tocilizumab, and longer duration of follow-up is
needed. Additionally, lack of standardized dosing strategies for tocilizumab further complicates interpretation
of secondary infection rates following administration.
Corticosteroids
Corticosteroids have emerged as a front-line treatment
option for SARS-CoV-2, but despite the proposed efficacy, safety data on corticosteroids in SARS-CoV-2
remain unclear. The largest randomized trial of corticosteroids in SARS-CoV-2 to date, RECOVERY, failed
to report the incidence of adverse events, including secondary infections (71). Furthermore, after the results
of RECOVERY were published, additional trials were
terminated early because equipoise for withholding
corticosteroids was no longer present, further limiting
the analysis of secondary infections. The incidence and
risk of secondary infections remains unclear and is of
great concern in the context of SARS-CoV-2 infection.
A summary of studies reporting secondary infections
in SARS-CoV-2 patients treated with corticosteroids is
presented in Table 2. Of the available studies, minimal
to no increase in risks of secondary bacterial or fungal
infections has been found after 28 days of follow-up,
regardless of the steroid used (dexamethasone, hydrocortisone, and methylprednisolone) (72–74). Although
findings were not statistically significant, most of these
8     www.ccejournal.org

studies were terminated early or largely underpowered.
Additionally, these studies had varying definitions and
methods of detecting secondary infections ranging
from positive microbiological cultures to physician discretion and use of antibiotic therapy. Corticosteroid
use was common in our study population (89.9%) and
reflects the published literature supporting efficacy of
corticosteroids that became available during our study
period. Overall, 49.8% of patients who received corticosteroids developed at least one secondary infection
in our population, and this is higher than previously
published rates ranging from 21.9% to 37.7% (72, 73).
This could be due to the longer duration of follow-up
to death or hospital discharge performed in our study
than was done in previous studies.
Reactivation of latent viral infections has been
described with corticosteroid use in the setting of
SARS-CoV-2 infection. Although overall HSV reactivation rate was low (7.2%) in our study population, all
patients experiencing HSV reactivation received corticosteroids. Limited data are available on viral reactivation following corticosteroid use in SARS-CoV-2
infection; however, the observed rate in our study is
much higher than previously reported. In a retrospective study of 38 ICU patients who experienced
Herpesviridae pulmonary reactivations, 44% in the
reactivation group received corticosteroids compared
with only 20% in the nonreactivation group (39).
Although not statistically significant, the clinical significance of Herpesviridae reactivation in patients with
corticosteroids should raise concern given the prevalence of this disease largely arises in immunocompromised hosts and may lead to fatal outcomes. Recently,
Kuindersma et al (75) proposed tailoring immune
modulation rather than targeting inflammation with
corticosteroids in all COVID-19 patients. They suggest
using variables such as fever, heart rate, CRP, and microbiological workup to help address whether steroids
should be initiated, changed, or stopped. This suggestion stems from the concern of patients becoming more
susceptible to secondary infections following the utilization of corticosteroids. Authors found that within
the first wave of COVID-19 between March and May
2020, 2% of patients were diagnosed with HSV pneumonitis, and during the second wave from September
to November 2020, 19% of patients were diagnosed
with HSV pneumonitis. They suggest this difference in
HSV pneumonitis may be due to the stark contrast of
July 2021 • Volume 3 • Number 7
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TABLE 2.

Studies Reporting Secondary Infections in Coronavirus Disease 2019 Patients Treated
With Corticosteroids
References

Study
Design/
Population

Intervention

Secondary
Infections

Tomazini
et al (72)

Multicenter,
Dexamethasone IV
randomized,
vs placebo
open-label trial

CoDEX

299 ICU patients Dose: 20 mg × 5 d, BSI: 7.9% vs
then 10 mg × 5 d
9.5%

21.9% vs
29.1%

Follow-up
Duration
28 d

Secondary
Infection
Definition
Not reported

Comments
88.1% vs 86.5% were
receiving other concomitant antibiotics
Trial halted early

151 (51%)
Duration: 10 d or
received
until ICU disdexamethasone
charge
Dequin
et al (73)

Multicenter,
randomized,
double-blind,
placebocontrolled trial

CAPE
COVID

149 ICU patients Dose: 200 mg/d ×
7 d, 100 mg/d
× 4 d, 50 mg/d
×3d

Hydrocortisone
continuous infusion vs placebo

37.7% vs 41.1%;
hazard ratio
0.81 (0.49–
1.35)

28 d

At discretion of
Could use quicker
provider and
8 d taper if respimust have been ratory status was
treated with
improved by day 4
antibiotics
Trial halted early

76 (51%) received Duration: 14 d
hydrocortisone
Jeronimo
Single-center,
et al 2020
randomized,
(74)
double-blind,
placebocontrolled trial

Methylprednisolone BSI at day 7:
IV v placebo
8.3% vs 8%

MetCOVID

393 hospitalized
patients

Dose: 0.5 mg/kg
bid

194 (49%) received methylprednisolone

Duration: 5 d

Le Balc’h
Single-center,
et al 2020
retrospective
(39)
study

—

28 d

Positive blood
culture

Standard of care
included antibiotics
for communityacquired
pneumonia
coverage

Sepsis at day
28: 38.1% vs
38.7%

Herpesviridae
reactivation
occurred in
47.4%

Not
Viral infections
44% vs 20% received
reported
tested twice
steroids
weekly using
quantitative
real-time polymerized chain
reaction on tracheal aspirates

38 mechanically
ventilated
patients
BSI = bloodstream infection.
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corticosteroid recommendations in early versus later
phases of COVID-19.
Given the imprecisions of the data, the WHO
recommends corticosteroids with low certainty in
SARS-CoV-2 by extrapolating evidence from acute
respiratory distress syndrome, pneumonia, and sepsis
studies and continues to suggest the risk of secondary
infections in these conditions is low (risk ratio, 1.01;
CI, 0.9–1.13) (76).

LIMITATIONS AND FUTURE
DIRECTIONS
Several limitations in our case series should be acknowledged, namely the single-center, retrospective
design. Additionally, our overall sample size was
relatively small. We also did not assess the association of secondary infections with clinical outcomes
in our study; however, it is logical that secondary
infectious complications would contribute to poor
clinical outcomes. Secondary bacterial, fungal, and
viral infections can be common among patients with
SARS-CoV-2 due to disease pathophysiology as well
as immunosuppressive therapies. Additional studies are needed to establish the impact of secondary
infections on clinical prognosis and outcomes in
patients with SARS-CoV-2. Several risk factors for
contracting SARS-CoV-2 and developing severe disease have been identified (77, 78). Risk factors for
developing secondary infections following immunosuppressive therapies for SARS-CoV-2 may certainly
exist; however, identification is lacking at this time.
Future studies working to identify such risk factors
may help select patients who require closer monitoring for infection following treatment or patients in
which certain immunosuppressive therapies should
be avoided. If immunosuppressive therapies such
as tocilizumab or corticosteroids are used, clinicians should vigilantly monitor for the development of secondary infections following treatment.
Unfortunately, little is known regarding the chronological association between immunosuppressive
therapies and secondary infections in patients with
SARS-CoV-2. Future studies should aim to characterize the timeline of developing secondary infections in patients with SARS-CoV-2 who are treated
with tocilizumab, corticosteroids, or other immunosuppressive therapies to aid in infection surveillance
and reporting.
10     www.ccejournal.org

CONCLUSIONS
Secondary infections occur frequently in ICU patients
being treated for SARS-CoV-2 infection, with tocilizumab and corticosteroid exposure potentially increasing risk. Future studies are needed with long-term
follow-up of clinical outcomes to identify risk factors
and mitigation strategies of secondary infections in
patients with SARS-CoV-2 treated with these therapies.

ACKNOWLEDGMENTS
We thank Dr. Jamie Sturgill (University of Kentucky,
College of Medicine, Department of Pulmonary,
Critical Care, and Sleep Medicine) for her help with
article revision.
1 Department of Pharmacy Practice, University of Kentucky,
College of Pharmacy, Lexington, KY.
2 Department of Pulmonary, Critical Care, and Sleep Medicine,
University of Kentucky, College of Medicine, Lexington, KY.
Supplemental digital content is available for this article. Direct
URL citations appear in the printed text and are provided in the
HTML and PDF versions of this article on the journal’s website
(http://journals.lww.com/ccejournal).
The authors have disclosed that they do not have any conflicts
of interest.
For information regarding this article, E-mail: brittany.bissell@uky.
edu

REFERENCES
1. Solomon CG, Gandhi RT, Lynch JB, et al: Mild or moderate
COVID-19. N Engl J Med 2020; 18:1757–1766
2. Gordon A, Mouncey P, Al-Beidh F: Interleukin-6 receptor
antagonists in critically ill patients with Covid-19. N Engl J Med
2021; 384:1491–1502
3. Rosas IO, Bräu N, Waters M, et al: Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med
2021; 384:1503–1516
4. Zhou P, Yang XL, Wang XG, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature
2020; 579:270–273
5. Zhao Y, Zhao Z, Wang Y, et al: Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. bioRxiv. Published
online April 9, 2020. doi: 10.1101/2020.01.26.919985
6. Shang J, Ye G, Shi K, et al: Structural basis of receptor recognition by SARS-CoV-2. Nature 2020; 581:221–224
7. Huang C, Wang Y, Li X, et al: Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet
2020; 395:497–506
8. Channappanavar R, Fehr AR, Zheng J, et al: IFN-I response
timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest 2019; 129:3625–3639
July 2021 • Volume 3 • Number 7

Narrative Review
9. Cervantes-Barragán L, Kalinke U, Züst R, et al: Type I IFN-mediated
protection of macrophages and dendritic cells secures control of
murine coronavirus infection. J Immunol 2009; 182:1099–1106
10. Schneider WM, Chevillotte MD, Rice CM: Interferon-stimulated
genes: A complex web of host defenses. Annu Rev Immunol
2014; 32:513–545
11. Uzé G, Schreiber G, Piehler J, et al: The receptor of the type I
interferon family. In: Interferon: The 50th Anniversary. Vol. 316.
Berlin, Germany, Springer, 2007, pp 71–95
12. Crouse J, Kalinke U, Oxenius A: Regulation of antiviral T
cell responses by type I interferons. Nat Rev Immunol 2015;
15:231–242
13. Rose KM, Elliott R, Martínez-Sobrido L, et al: Murine coronavirus delays expression of a subset of interferon-stimulated
genes. J Virol 2010; 84:5656–5669
14. Zhao L, Jha BK, Wu A, et al: Antagonism of the interferoninduced OAS-RNase L pathway by murine coronavirus ns2
protein is required for virus replication and liver pathology. Cell
Host Microbe 2012; 11:607–616
15. Totura AL, Baric RS: SARS coronavirus pathogenesis: Host
innate immune responses and viral antagonism of interferon.
Curr Opin Virol 2012; 2:264–275
16. Lokugamage K, Hage A, de Vries M, et al: Type I interferon susceptibility distinguishes SARS-CoV-2 from
SARS-CoV. bioRxiv. Published online July 13, 2020. doi:
10.1101/2020.03.07.982264
17. Huang Y, Chen S, Yang Z, et al: SARS-CoV-2 viral load in clinical samples from critically ill patients. Am J Respir Crit Care
Med 2020; 201:1435–1438
18. Bakaletz LO: Viral-bacterial co-infections in the respiratory
tract. Curr Opin Microbiol 2017; 35:30–35
19. Vareille M, Kieninger E, Edwards MR, et al: The airway epithelium: Soldier in the fight against respiratory viruses. Clin
Microbiol Rev 2011; 24:210–229
20. Avadhanula V, Rodriguez CA, Devincenzo JP, et al: Respiratory
viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent
manner. J Virol 2006; 80:1629–1636
21. Hanada S, Pirzadeh M, Carver KY, et al: Respiratory viral infection-induced microbiome alterations and secondary bacterial
pneumonia. Front Immunol 2018; 9:2640
22. Dewals BG, Machiels B, Liang X, et al: “Novel” triggers of herpesvirus reactivation and their potential health relevance. Front
Microbiol 2019; 1:3207
23. Garcia-Vidal C, Sanjuan G, Moreno-García E, et al; COVID-19
Researchers Group: Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study. Clin Microbiol Infect 2021; 27:83–88
24. Giacobbe DR, Battaglini D, Ball L, et al: Bloodstream infections
in critically ill patients with COVID-19. Eur J Clin Invest 2020;
50:e13319
25. Lansbury L, Lim B, Baskaran V, et al: Co-infections in people
with COVID-19: A systematic review and meta-analysis. J
Infect 2020; 81:266–275
26. Chen X, Zhao B, Qu Y, et al: Detectable serum SARS-CoV-2
viral load (RNAaemia) is closely correlated with drastically
elevated interleukin 6 (IL-6) level in critically ill COVID-19
patients. Clin Infect Dis 2020; 6:ciaa449
Critical Care Explorations

27. Luyt CE, Sahnoun T, Gautier M, et al: Ventilator-associated
pneumonia in patients with SARS-CoV-2-associated acute
respiratory distress syndrome requiring ECMO: A retrospective cohort study. Ann Intensive Care 2020; 10:158
28. Razazi K, Arrestier R, Haudebourg AF, et al: Risks of ventilatorassociated pneumonia and invasive pulmonary aspergillosis in
patients with viral acute respiratory distress syndrome related
or not to Coronavirus 19 disease. Crit Care 2020; 24:699
29. Hughes S, Troise O, Donaldson H, et al: Bacterial and fungal
coinfection among hospitalized patients with COVID-19: A
retrospective cohort study in a UK secondary-care setting. Clin
Microbiol Infect 2020; 26:1395–1399
30. Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al; DutchBelgian Mycosis study group: Invasive aspergillosis in patients
admitted to the intensive care unit with severe influenza: A retrospective cohort study. Lancet Respir Med 2018; 6:782–792
31. Arastehfar A, Carvalho A, van de Veerdonk FL, et al: COVID19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi (Basel) 2020; 6:91
32. van Arkel ALE, Rijpstra TA, Belderbos HNA, et al: COVID-19associated pulmonary aspergillosis. Am J Respir Crit Care Med
2020; 202:132–135
33. Koehler P, Cornely OA, Böttiger BW, et al: COVID-19 associated pulmonary aspergillosis. Mycoses 2020; 63:528–534
34. Fekkar A, Lampros A, Mayaux J, et al: Occurrence of invasive
pulmonary fungal infections in severe COVID-19 patients admitted to the ICU. Am J Respir Crit Care Med 2020; 203:307–317
35. Pemán J, Ruiz-Gaitán A, García-Vidal C, et al: Revista
Iberoamericana de Micología fungal co-infection in COVID-19
patients: Should we be concerned? Rev Iberoam Micol 2020;
37:41–46
36. White PL, Dhillon R, Cordey A, et al: A national strategy to diagnose coronavirus disease 2019–associated invasive fungal disease in the intensive care unit. Clin Infect Dis 2020:ciaa1298
37. Luyt CE, Combes A, Deback C, et al: Herpes simplex virus lung
infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007; 175:935–942
38. Saugel B, Jakobus J, Huber W, et al: Herpes simplex virus
in bronchoalveolar lavage fluid of medical intensive care unit
patients: Association with lung injury and outcome. J Crit Care
2016; 32:138–144
39. Le Balc’h P, Pinceaux K, Pronier C, et al: Herpes simplex virus
and cytomegalovirus reactivations among severe COVID-19
patients. Crit Care 2020; 24:530
40. Hardy A: Genentech Inc. Actemra (tocilizumab) Injection Package
Insert. South San Francisco, CA, Genentech Inc, 2018, pp 1–40
41. Lan SH, Lai CC, Huang HT, et al: Tocilizumab for severe
COVID-19: A systematic review and meta-analysis. Int J
Antimicrob Agents 2020; 56:106103
42. Aziz M, Haghbin H, Abu Sitta E, et al: Efficacy of tocilizumab
in COVID-19: A systematic review and meta-analysis. J Med
Virol 2021; 93:1620–1630
43. Stone JH, Frigault MJ, Serling-Boyd NJ, et al; BACC Bay
Tocilizumab Trial Investigators: Efficacy of Tocilizumab in Patients
Hospitalized with Covid-19. N Engl J Med 2020; 383:2333–2344
44. Salama C, Han J, Yau L, et al: Tocilizumab in patients hospitalized with covid-19 pneumonia. N Engl J Med 2021;
384:20–30
www.ccejournal.org

    11

Behal et al
45. Calderón-Goercke M, Loricera J, Aldasoro V, et al: Tocilizumab
in giant cell arteritis. Observational, open-label multicenter
study of 134 patients in clinical practice. Semin Arthritis Rheum
2019; 49:126–135
46. Yamamoto K, Goto H, Hirao K, et al: Longterm safety of tocilizumab: Results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J
Rheumatol 2015; 42:1368–1375
47. Chiu YM, Chen DY: Infection risk in patients undergoing treatment for inflammatory arthritis: Non-biologics versus biologics.
Expert Rev Clin Immunol 2020; 16:207–228
48. Coutinho AE, Chapman KE: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments
and mechanistic insights. Mol Cell Endocrinol 2011; 335:2–13
49. Wu J, Keeley A, Mallen C, et al: Incidence of infections associated with oral glucocorticoid dose in people diagnosed with
polymyalgia rheumatica or giant cell arteritis: A cohort study in
England. CMAJ 2019; 191:E680–E688
50. Waljee AK, Rogers MAM, Lin P, et al: Short term use of oral
corticosteroids and related harms among adults in the United
States: Population based cohort study. BMJ 2017; 357:j1415
51. Britt RC, Devine A, Swallen KC, et al: Corticosteroid use
in the intensive care unit: At what cost? Arch Surg 2006;
141:145–149
52. Joshi N, Caputo GM, Weitekamp MR, et al: Infections in patients
with diabetes mellitus. N Engl J Med 1999; 341:1906–1912
53. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of
sepsis in the United States from 1979 through 2000. N Engl J
Med 2003; 348:1546–1554
54. de Roquetaillade C, Mansouri S, Brumpt C, et al: Comparison
of circulating immune cells profiles and kinetics between coronavirus disease 2019 and bacterial sepsis. Crit Care Med
2021 May 18. [online ahead of print]
55. Alattar R, Ibrahim TBH, Shaar SH, et al: Tocilizumab for the
treatment of severe coronavirus disease 2019. J Med Virol
2020; 92:2042–2049
56. Campochiaro C, Della-Torre E, Cavalli G, et al; TOCI-RAF Study
Group: Efficacy and safety of tocilizumab in severe COVID19 patients: A single-centre retrospective cohort study. Eur J
Intern Med 2020; 76:43–49
57. Vu CA, DeRonde KJ, Vega AD, et al: Effects of tocilizumab
in COVID-19 patients: A cohort study. BMC Infect Dis 2020;
20:964
58. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al: Tocilizumab in
patients with severe COVID-19: A retrospective cohort study.
Lancet Rheumatol 2020; 2:e474–e484
59. Biran N, Ip A, Ahn J, et al: Tocilizumab among patients with
COVID-19 in the intensive care unit: A multicentre observational study. Lancet Rheumatol 2020; 2:e603–e612
60. Toniati P, Piva S, Cattalini M, et al: Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center
study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;
19:102568
61. Rossotti R, Travi G, Ughi N, et al; Niguarda COVID-19 Working
Group: Safety and efficacy of anti-il6-receptor tocilizumab use
in severe and critical patients affected by coronavirus disease
2019: A comparative analysis. J Infect 2020; 81:e11–e17
12     www.ccejournal.org

62. Somers EC, Eschenauer GA, Troost JP, et al: Tocilizumab for
treatment of mechanically ventilated patients with COVID-19.
Clin Infect Dis 2020 Jul 11. [online ahead of print]
63. Lewis TC, Adhikari S, Tatapudi V, et al: A propensity-matched
cohort study of tocilizumab in patients with coronavirus disease 2019. Crit Care Explor 2020; 2:e0283
64. Hermine O, Mariette X, Tharaux P-L, et al: Effect of tocilizumab vs usual care in adults hospitalized with COVID-19
and moderate or severe pneumonia. JAMA Intern Med 2020;
181:32–40
65. Salvarani C, Dolci G, Massari M, et al: Effect of tocilizumab
vs standard care on clinical worsening in patients hospitalized
with COVID-19 pneumonia: A randomized clinical trial. JAMA
Intern Med 2021; 181:24–31
66. Gordon AC, Mouncey PR, Al-Beidh F: Interleukin-6 receptor antagonists in critically ill patients with Covid-19preliminary report. MedRX. Published online 2021. doi:
10.1101/2021.01.07.21249390
67. Koike T, Harigai M, Inokuma S, et al: Effectiveness and safety of
tocilizumab: Postmarketing surveillance of 7901 patients with
rheumatoid arthritis in Japan. J Rheumatol 2014; 41:15–23
68. Yun H, Xie F, Delzell E, et al: Risks of Herpes Zoster in patients
with rheumatoid arthritis according to biologic disease modifying therapy. Arthritis Care Res 2015; 67:731–736
69. Schiff MH, Kremer JM, Jahreis A, et al: Integrated safety in
tocilizumab clinical trials. Arthritis Res Ther 2011; 13:R141
70. Sebba A: Tocilizumab: The first interleukin-6-receptor inhibitor.
Am J Health Syst Pharm 2008; 65:1413–1418
71. Horby P, Lim WS, Emberson JR, et al: Dexamethasone in hospitalized patients with Covid-19 — preliminary Report. N Engl J
Med 2021; 384:693–704
72. Tomazini BM, Maia IS, Cavalcanti AB, et al; COALITION
COVID-19 Brazil III Investigators: Effect of dexamethasone on
days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The
CoDEX randomized clinical trial. JAMA 2020; 324:1307–1316
73. Dequin PF, Heming N, Meziani F, et al; CAPE COVID Trial
Group and the CRICS-TriGGERSep Network: Effect of hydrocortisone on 21-day mortality or respiratory support among
critically ill patients with COVID-19: A randomized clinical trial.
JAMA 2020; 324:1298–1306
74. Jeronimo CMP, Farias MEL, Val FFA, et al: Methylprednisolone
as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A randomized,
double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis
2021; 72:e373–e381
75. Kuindersma M, Diaz RR, Spronk PE: Tailored modulation of the
inflammatory balance in COVID - 19 patients admitted to the
ICU ?— a viewpoint. Crit Care. 2021; 25:178
76. World Health Organization: Corticosteroids for COVID-19.
2020. Available at: https://www.who.int/publications/i/item/
WHO-2019-nCoV-Corticosteroids-2020.1
77. Wu C, Chen X, Cai Y, et al: Risk factors associated with acute
respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA
Intern Med 2020; 180:934–943
78. Zhou F, Yu T, Du R, et al: Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China:
A retrospective cohort study. Lancet 2020; 395:1054–1062
July 2021 • Volume 3 • Number 7

